The RTF letter does in fact mention syringes: D.
Post# of 148052
Quote:
D. Device-Related Issues
No data from studies conducted with the drug in the device were included in the submission, and no information is included on the manufacturer of the syringe and needles.
So, he was correct to mention this as a problem. But, who knows what Amarex told him as to emphasis of which was the largest problem.